According to the terms of the agreement, Valeritas will be responsible for product development, regulatory approval, manufacturing and quality management while NZMS Diabetes will take over the sales, marketing, customer support and distribution responsibilities in New Zealand.
“We are delighted to announce patients with Type 2 diabetes in New Zealand now have access to V-Go wearable insulin delivery device,” CEO John Timberlake said in prepared remarks.
“Clinical studies have demonstrated that patients using our all-in-one insulin delivery device can enjoy better control over blood sugar levels while using less insulin. This represents the first country outside of the United States in which our flagship product V-Go has been launched, and we look forward to the introduction of V-Go in additional countries as we expand our distribution network,” Timberlake added.
In June, Valeritas touted positive results from its Enable study, showing that patients who switched from insulin pens and syringes to the V-Go device experienced improved blood glucose levels and lowered their daily insulin dose.